Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products. As of the reporting date, the company had one approved product, ARCALYST (rilonacept), for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), which became available for prescription in late March 2008. The company maintains significant strategic collaborations with sanofi-aventis (aflibercept and antibody discovery) and Bayer HealthCare (VEGF Trap-Eye).
Key Financial Metrics
| Metric (in thousands) | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenues | $56,383 | $15,788 |
| Research & Development Expenses | $61,270 | $41,235 |
| Selling, General & Administrative Expenses | $11,024 | $8,202 |
| Net Loss | $(11,618) | $(29,917) |
| Net Loss Per Share (Basic & Diluted) | $(0.15) | $(0.46) |
| Cash and Cash Equivalents (End of Period) | $520,875 | $156,484 |
| Marketable Securities (Total) | $305,383 | N/A |
| Convertible Notes Payable | $200,000 | $200,000 |
Note: All figures in thousands except per share data. Total liquid assets (cash, restricted cash, and marketable securities) at March 31, 2008, were approximately $827.9 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by approximately 257% to $56.4 million from $15.8 million. This was driven primarily by increased contract research and development revenue from sanofi-aventis ($35.7 million vs. $11.8 million) and Bayer HealthCare ($9.0 million vs. $0), as well as technology licensing revenue ($10.0 million vs. $2.1 million).
- Expense Increases: Operating expenses rose to $72.3 million from $49.4 million. Research and development (R&D) expenses increased by $20.1 million, largely due to higher clinical trial costs for VEGF Trap-Eye and ARCALYST, increased clinical manufacturing costs, and higher payroll due to headcount growth (714 employees vs. 585).
- Improved Net Loss: Despite higher expenses, the net loss narrowed significantly to $11.6 million from $29.9 million, primarily due to the substantial increase in collaboration revenues.
- Cash Position: Cash and cash equivalents increased by $21.9 million during the quarter. Net cash used in operating activities was $17.9 million, compared to $9.2 million in the prior year, while investing activities provided $37.9 million due to net sales of marketable securities.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- ARCALYST Commercialization: The company launched ARCALYST in March 2008. However, management anticipates that commercialization of ARCALYST for CAPS will not materially impact cash flows in 2008 due to the rarity of the disease (approx. 1 in 1,000,000 people). Revenue recognition for product sales is deferred until return and rebate estimates can be reasonably determined.
- Capital Resources: Management believes existing capital resources, including funding from collaborations, will meet operating needs through at least 2012. The company expects to incur substantial losses over the next several years as it advances clinical programs.
- Capital Expenditures: The company expects to incur approximately $55 to $65 million in capital expenditures for the remainder of 2008, primarily for expanding manufacturing capacity in Rensselaer, NY, and tenant improvements for a new lease in Tarrytown, NY.
Risks and Contingencies
- Debt Maturity: The company has $200 million in convertible senior subordinated notes maturing in October 2008. If the stock price is not above the conversion price ($30.25) at maturity, the company must repay the principal from existing resources or refinance.
- Intellectual Property Dispute: Cellectis Inc. claims Regeneron's use of VelocImmune technology and certain agreements are outside the scope of a 2003 license. Cellectis has requested Regeneron cease using the licensed patents. Regeneron disagrees and is in discussions, but potential litigation could result in material losses.
- Collaboration Reliance: The company relies heavily on sanofi-aventis and Bayer HealthCare for funding and commercialization of key pipeline assets (aflibercept, VEGF Trap-Eye, and antibody candidates). Termination of these agreements would materially harm operations.
- Regulatory and Clinical Risks: Success of product candidates is uncertain. Clinical trials are expensive and time-consuming. Side effects or failure to demonstrate efficacy could halt development.
Key Facts for Investor Verification
- Debt Refinancing: Verify the company's ability to refinance or convert the $200 million convertible notes maturing in October 2008, given the current stock price relative to the $30.25 conversion price.
- ARCALYST Sales Trajectory: Monitor actual product sales and revenue recognition for ARCALYST, as management expects minimal cash flow impact in 2008 due to the small patient population for CAPS.
- Cellectis Litigation: Track the status of the dispute with Cellectis Inc. regarding the VelocImmune license, as a negative outcome could restrict core technology usage.
- Clinical Trial Results: Watch for data readouts from Phase 3 trials for aflibercept (oncology) and VEGF Trap-Eye (wet AMD), which are critical for future revenue milestones and commercialization.
- Capital Expenditure Execution: Verify the progress and cost of the planned $55-$65 million capital expenditure program for manufacturing expansion and new facilities.